A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
Condition(s):T-Cell Lymphoma; Relapsed T-Cell Lymphoma; Refractory T-Cell LymphomaLast Updated:March 6, 2017Terminated
Hide Studies Not Open or Pending
Condition(s):T-Cell Lymphoma; Relapsed T-Cell Lymphoma; Refractory T-Cell LymphomaLast Updated:March 6, 2017Terminated
Condition(s):Non-hodgkins Lymphoma; Hodgkins Lymphoma; Multiple MyelomaLast Updated:July 24, 2017Terminated
Condition(s):Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal NeoplasmsLast Updated:October 9, 2015Completed
Condition(s):Acute Lymphoblastic LeukaemiaLast Updated:May 20, 2013Terminated
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:April 21, 2017Completed
Condition(s):Immune Checkpoint Inhibitor; Chemotherapy Effect; Epigenetic Disorder; NK/T-cell Lymphoma of Nasal CavityLast Updated:July 7, 2020Recruiting
Condition(s):Acute Lymphoblastic Leukemia; Lymphoblastic LymphomaLast Updated:November 3, 2023Active, not recruiting
Condition(s):Extranodal NK/T Cell LymphomaLast Updated:June 22, 2022Not yet recruiting
Condition(s):Tumors; LymphomaLast Updated:May 20, 2008Terminated
Condition(s):Nasal Type Extranodal NK/T-Cell LymphomaLast Updated:March 11, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.